EGFR inhibitors and autophagy in cancer treatment (Q38257898)

1 September 2017

1 reference

title

EGFR inhibitors and autophagy in cancer treatment (English)

1 reference

1 September 2017

0 references

Jie Cui

1

1 reference

1 September 2017

Yun-Feng Hu

2

1 reference

1 September 2017

Xie-Min Feng

3

1 reference

1 September 2017

Tao Tian

4

1 reference

1 September 2017

Ya-Huan Guo

5

1 reference

1 September 2017

Jun-Wei Ma

6

1 reference

1 September 2017

Ke-Jun Nan

7

1 reference

1 September 2017

Hong-Yi Zhang

8

1 reference

1 September 2017

publication date

9 October 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

35

1 reference

1 September 2017

issue

12

1 reference

1 September 2017

page(s)

11701-11709

1 reference

1 September 2017

cites work

Functions of lysosomes

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Autophagy revisited: a conversation with Christian de Duve

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Eaten alive: a history of macroautophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

The expanding TOR signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Regulation of macroautophagy by mTOR and Beclin 1 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Beclin-1: autophagic regulator and therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Activation of mTORC2 by association with the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

The dynamic nature of autophagy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Complex regulation of autophagy in cancer - integrated approaches to discover the networks that hold a double-edged sword.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

PI 3-kinase and cancer: changing accents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Ras is involved in the negative control of autophagy through the class I PI3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Disruption of autophagy at the maturation step by the carcinogen lindane is associated with the sustained mitogen-activated protein kinase/extracellular signal-regulated kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Peptide combinatorial libraries identify TSC2 as a death-associated protein kinase (DAPK) death domain-binding protein and reveal a stimulatory role for DAPK in mTORC1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Survival of cancer cells is maintained by EGFR independent of its kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Mitochondrially localized EGFR is subjected to autophagic regulation and implicated in cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Gefitinib in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

DRAM, a p53-induced modulator of autophagy, is critical for apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

DRAM links autophagy to p53 and programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Analysis of DRAM-related proteins reveals evolutionarily conserved and divergent roles in the control of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Regulation of autophagy by cytoplasmic p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

EGFR tyrosine kinase inhibition induces autophagy in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Autophagy contributes to gefitinib-induced glioma cell growth inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2660-Z

Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25293518

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dissecting the role of mTOR: lessons from mTOR inhibitors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25293518

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25293518

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-014-2660-Z

1 reference

Dimensions Publication ID

1 September 2017

1016407072

0 references

1 reference